NCT03925194View on ClinicalTrials.gov

A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF

PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Cystic Fibrosis, 10011762
Interventions
DRUG

Anakinra

Application of Anakinra once daily for 28 days

Trial Locations (3)

13353

RECRUITING

Charité - Universitätsmedizin Berlin, Berlin

45239

RECRUITING

Universitätsmedizin Essen, Ruhrlandklinik, Essen

69120

RECRUITING

University Children's Hospital Heidelberg, Cystic Fibrosis Centre, Heidelberg

All Listed Sponsors
lead

Heidelberg University

OTHER